Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study

The aim of the study was to investigate NAT1,
NAT2, GSTM1, GSTT1, GSTP1, SULT1A1, XRCC1,
XRCC3 and XPD genetic polymorphisms, coffee consumption
and risk of bladder cancer (BC) through a
hospital-based case–control study. The study population
included 197 incident BC cases and 211 controls. The
association between genetic polymorphisms, coffee drinking
and BC risk was assessed by logistic regression taking
into account age, education, tobacco smoking and occupational
exposures to polycyclic aromatic hydrocarbons
and aromatic amines. No association was found between
the genetic polymorphisms investigated and BC risk
according to coffee consumption apart of a significant
increased BC risk among GSTP1 105-114 Val carriers
heavy coffee drinkers ([3 cups/day) (OR 3.18, 95%CI
1.06–9.55). In conclusion our findings suggest a very
limited role, if any, of genetic polymorphisms investigated
in modulating the BC risk in coffee drinkers.